

S6. Characteristics of Published Systematic Reviews identified in COVID-19 L-OVE for prevention

Table 5 Characteristics of Published Systematic Reviews identified in COVID-19 L-OVE for prevention of COVID-19

Author, Year	Country of affiliation of the review ^a	Review type	Population	Intervention	Main Outcome(s) reported	N studies for COVID-19 included (study types)	Protocol published prior to publication?	Type of publication, Comments (e.g. DOI, Link, PROSPERO registration)
Public health interventions (n=21)								
Ayouni, 2021	Tunisia	SR	general population	PHI (e.g., social distancing, lockdown, travel restrictions, etc.)	transmission of COVID-19 (effectiveness in preventing and controlling the spread of COVID-19)	18 (2 ITS, 16 NRSI)	Yes, PROSPERO	journal publication 10.1186/s12889-021-11111-1 CRD42020196018
Burns, 2020	Germany	rapid SR	travellers (general population)	travel-related control measures during the COVID-19 pandemic, or SARS, MERS	effectiveness	13 (NRSI), 49 (MS)	Yes, peer-reviewed Cochrane protocol	Cochrane review https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013717.pub2/full
Chetty, 2020	South Africa	rapid SR	travelling populations (general population)	travel screening practices (e.g., body temperature measures, airport screening,...)	effectiveness	0; 4 (MS)	No	journal publication 10.7196/SAMJ.2020.v110i1.1.14959
Chisale, 2020	Malawi	SR	population in low- and middle-income countries (general population)	community-based interventions to prevent COVID-19 transmission	COVID-19 transmission	6 (NRSI)	Yes, PROSPERO	preprint 10.21203/rs.3.rs-98441/v1 CRD42020204984
Chu, 2020	Canada	SR, MA	people in healthcare or non-healthcare settings (mixed population)	social distancing, face mask, eye protection	person-to-person transmission of COVID-19, SARS, MERS	64 (NRSI)	Yes, PROSPERO	journal publication and preprint 10.1016/S0140-6736(20)31142-9 CRD42020177047
Chung, 2020	UK	rapid SR, case study	n.r. (most likely general population)	testing, contact tracing, isolation policies	COVID-19 prevention and control	n.r. (48 with SR, guidelines also included)	No	preprint 10.1101/2020.06.04.20122614
Frazer, 2020	Ireland	rapid SR	older people in long term care facilities, employees, visitors	any intervention to reduce transmission, e.g., facility	transmission of COVID-19, SARS, MERS	34 (NRSI)	Yes, PROSPERO	preprint 10.1101/2020.10.29.20222182

			(high risk population)	measures, PPE, hygiene, social distancing				CRD42020191569
Girum, 2020	Ethiopia	SR	persons after exposure to COVID-19 or at high risk or living in areas with an outbreak (high risk population)	contact tracing, screening, quarantine, isolation	effectiveness for COVID-19 prevention (incidence, transmission, ...)	9 (NRSI), 13 (MS)	No	journal publication 10.1186/541182-020-00285-W
Grépin, 2020	China	rapid SR	travelling populations during COVID-19 pandemic (general population)	travel-related measures (e.g. travel advice, entry and exit screening, ...)	no restrictions (e.g. epidemiological, non-epidemiological outcomes)	3 (NRSI), 26 (MS)	No	journal publication and preprint 10.1136/bmjgh-2020-004537
Johanna, 2020	Indonesia	SR, MA	general population during COVID-19 pandemic	mass screening, lockdown, combination of both	COVID-19 prevention (transmission, incidence, ...)	4 (NRSI), 10 (MS)	Yes, PROSPERO	journal publication 10.4081/jphr.2020.2011 CRD42020190546
Juneau, 2020	USA, COVID-19 Work Group	SR	n.r. (most likely general population)	contact tracing	effectiveness	14 (NRSI), 18 (MS)	Yes, PROSPERO	preprint 10.1101/2020.07.23.20160234 CRD42020198462
Marasinghe, 2020	USA	SR	individuals not medically diagnosed with COVID-19 (general population)	public health recommendation for face masks	effectiveness in limiting the spread of COVID-19	0	No	journal publication and preprint 10.14202/IJOH.2020.109-117 10.21203/rs.3.rs-16701/v3
Mayr, 2020	Austria	rapid SR	contacts of infected cases; travellers, general population (COVID-10, SARS, MERS) (mixed population)	quarantine with or without other public health measures	effectiveness in suppression of COVID-19 outbreak	0; 10 (MS)	No	journal publication 10.1055/A-1164-6611
Mbwogge, 2021	UK	rapid SR	general population	mass testing with contact tracing vs testing of symptomatic individuals and contact tracing	effectiveness in suppression of COVID-19 outbreak	1 (NRSI), 11 (MS)	No	journal publication and preprint 10.2196/27254
Muhammed, 2020	Iraq	rapid SR	n.r. (most likely general population)	school closure	transmission of COVID-19 in the general population	3 (NRSI), 5 (MS)	No	journal publication 10.24017/COVID.12
Public Health England, 2021	Public Health England, UK	rapid SR	individuals in school setting (school population)	school based interventions (e.g., cohorting, distancing)	transmission of COVID-19	41 (NRSI), 15 (MS)	Yes, PROSPERO	update https://phe.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=9adedb17d5622f9cd7e42febca9ad CRD42020191867
Putri, 2020	Indonesia	SR	healthcare workers, not infected (high risk population)	preventive actions (social distancing, using PPE, handwashing, screening, etc.)	transmission of COVID-19	7 (n.r.)	No	journal publication 10.19106/JMEDSCISI005203202013

Regmi, 2021	UK	SR	any population during COVID-19 pandemic (mixed population)	PHI (isolation, social distance, quarantine)	COVID-19 incidence, risk of transmission reduction	33 (NRSI)	Yes, PROSPERO and peer-reviewed protocol	journal publication 10.3390/ijerph18084274 CRD42020207338
Viner, 2020	UK	rapid SR	population during COVID-19, SARS, MERS outbreaks (general population)	school closure	effectiveness in limiting the spread of COVID-19	4 (NRSI), 1 (MS)	No	journal publication and preprint 10.1016/S2352-4642(20)30095-X
Viswanathan, 2020	USA	rapid SR	general populations with unknown prevalence of SARS-coV-2	universal screening (mass screening) for SARS-CoV-2 infection vs no screening	effectiveness and screening test accuracy	2 (MS, effectiveness); 17 (NRSI or DTA studies), 3 (MS, DTA studies)	Yes, OSF.io	Cochrane Review 10.1002/14651858.CD013718
Walsh, 2021	UK	SR	general population	school closures, reopening, school holidays	transmission of COVID-19	40 (NRSI)	Yes, PROSPERO	preprint 10.1101/2021.01.02.21249146 CRD42020213699
Personal protective equipment (n=8)								
Al-Moraissi, 2020	Yemen	rapid SR	adult dental health care workers (high risk population)	respirators vs surgical masks	effectiveness against transmission of COVID-19, SARS, MERS	0	Yes, PROSPERO	preprint 10.1101/2020.11.20.20235333 CRD42020192912
de Camargo, 2020	Brasil	rapid SR	general population; SARS, MERS, COVID-19	non-woven face mask (surgical masks, N95, FFP) vs no use	prevention of coronavirus infections (efficacy of protection)	0	No	journal publication and preprint 10.1590/1413-81232020259.13622020
Dehaghi, 2020	Iran	SR	patients with COVID-19, individuals with high risk or exposure (high risk population)	face masks (N95, surgical, cotton)	different (transmission)	5 (NRSI)	No	journal publication 10.17533/UDEA.IEE.V38N2E13
Gross, 2021	Germany	rapid SR	healthcare workers, not infected (high risk population)	any preventive measures (e.g. PPE, hand hygiene)	benefits (in terms of COVID-19 infection) and risks (e.g. headache or facial skin lesions due to N95 respirators) of preventive measures in the healthcare setting	13 (NRSI)	No	journal publication 10.1136/bmjopen-2020-042270
Li, 2020	USA	SR, MA	Any population (mixed population)	face masks	transmission of COVID-19	6 (NRSI)	Yes, PROSPERO	journal publication and preprint 10.1016/j.ajic.2020.12.007 CRD42020211862

Morales Ferrer, 2021	Chile	living SR	healthy population (general population)	gloves	COVID-19 infections, hospitalisation, safety	1 (NRSI)	Yes, PROSPERO and peer-reviewed protocol	preprint 10.31219/osf.io/uz4rs CRD42020188674
Rohde, 2020	Ireland	rapid SR	community and household setting (general population)	face masks	effectiveness in prevention of SARS-CoV-2 transmission	7 (NRSI)	No	preprint 10.12688/HRBOPENRES.13161.1
Tabatabaei zadeh, 2021	Iran	SR, MA	asymptomatic individuals without COVID-19 and COVID-19 patients (high risk population)	face masks	transmission of COVID-19 (risk of COVID-19 infection)	4 (n.r.)	No	journal publication 10.1186/s40001-020-00475-6
Vaccination (n=8)								
Alimehmeti, 2021	Albania	SR	n.r. (phase III clinical trials) (most likely general population)	COVID-19 vaccines	clinical efficacy and safety	3 (phase III)	No	journal publication 10.32391/AJTES.V5i1.178
Del Riccio, 2020	Italy	SR	general population	influenza vaccination	risk of SARS-CoV-2 infection, severity, death	12 (NRSI)	No	journal publication and preprint 10.3390/ijerph17217870
Kaur, 2021	India	SR	any population during COVID-19 pandemic (mixed population)	COVID-19 vaccines	safety	11 (RCT, NRSI)	No	journal publication 10.1007/s12291-021-00968-z
Khera, 2020	India	SR, MA	countries with universal BCG vaccination policy vs. countries without (general population)	BCG vaccination	protection against COVID-19 infection, incidence, mortality	28 (NRSI)	Yes, PROSPERO	preprint 10.21203/rs.3.rs-97073/v1 CRD42020204466
Pormohamad, 2021	Canada	SR, MA	n.r. (most likely general population)	COVID-19 vaccines	efficacy, safety	25 (RCT, phase I-III)	No	journal publication https://pubmed.ncbi.nlm.nih.gov/34066475/
Sathian, 2021	Qatar	SR, MA	healthy adults (18+) (general population)	COVID-19 vaccines	safety, immunogenicity	14 (RCT, NRSI, phase I-III)	Yes, OSF.io	journal publication 10.3126/nje.v11i1.36163
Xing, 2021 ^b	China	SR	healthy adults (18+) (general population)	COVID-19 vaccines	efficacy, safety	13 (RCT)	No	journal publication 10.7499/j.issn.1008-8830.2101133
Yuan, 2021	China	SR, MA	healthy adults (18+), without history of SARS or COVID-19 (general population)	COVID-19 vaccines	safety, tolerability, immunogenicity	5 (RCT)	No	preprint 10.2139/ssrn.3746259
Pharmaceutical interventions (n=9)								
Bartoszkowski, 2021	Canada	living SR, NMA	people at risk of COVID-19 (pre-, post-exposure status and risk groups) (mixed population)	drugs for prophylaxis (HCQ, CQ, ivermectin, etc.)	effectiveness on COVID-19 (e.g. incidence, mortality) and SARS-CoV-2 infection	11 (RCT)	No	journal publication and preprint 10.1136/bmj.n949

Bryant, 2021	UK	SR, MA	patients with COVID-19, individuals with exposure or high risk (high risk population)	ivermectin	clinical efficacy and safety, incidence	post-exposure/high risk: 3 (RCT)	Yes, self-published (via tinyurl.com)	journal publication and preprint 10.1097/MJT.0000000000001402
Ford, 2020	Switzerland, World Health Organization	SR	patients with COVID-19, SARS or MERS, individuals with exposure (high risk population)	antiretroviral drugs (lopinavir/ritonavir, and others)	clinical efficacy and safety, incidence, transmission rate, ... (any clinical outcome)	post-exposure: 1 NRSI	No	journal publication 10.1002/JIA2.25489
García-Albéniz, 2020	USA; Spain	SR, MA	pre- or post-exposure, PCR-negative individuals (mixed population)	HCQ	COVID-19 infections (Risk Ratio)	5 (RCT)	No	preprint 10.1101/2020.09.29.20203869
Lewis, 2021	Canada	SR, MA	adults with exposure or high risk (high risk population)	HCQ	prophylaxis efficacy and safety; transmission, mortality, hospitalization	4 (RCT)	No	journal publication: 10.1371/journal.pone.0244778
Rodríguez-Gutiérrez, 2021	Mexico	living SR, MA	patients with COVID-19 (>16), individuals with exposure (high risk population)	ivermectin	clinical efficacy and safety	2 (RCT)	Yes, PROSPERO	preprint 10.2139/ssrn.3802499 CRD42021235402
Shah, 2020	India	SR	n.r. (most likely high risk population)	HCQ, CQ	prophylactic effect	0	No	journal publication 10.1111/1756-185X.13842
Singh, 2021	UK; Cochrane Infectious Diseases Group	SR, MA	patients with COVID-19, individuals at risk of exposure or post-exposure (high risk population)	CQ, HCQ	clinical efficacy and safety, incidence, antibodies, transmission (e.g. to household contacts), disease severity	pre-exposure: 0; post-exposure: 2 (RCT)	Yes, PROSPERO and peer-reviewed Cochrane protocol	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013587.pub2/full CRD42020185220
Smit, 2021	Switzerland	SR	any human population (e.g., high-risk older individuals, healthcare workers, healthy subjects) (mixed population)	pre- or post-exposure prophylaxis for COVID-19 (drug- or biologic-based; dietary supplements, herbal extracts)	impact on SARS-CoV-2 or COVID-19 incidence or prevalence	7 (RCT, NRSI)	No	journal publication 10.1016/j.cmi.2021.01.013
Other interventions (n=5)								
Bassatne, 2020	Lebanon	SR, MA	family members of adults with SARS, MERS, COVID-19 (high risk population)	vitamin D	clinical efficacy and safety, SARS-coV-2 positivity, transmission (to family members), disease severity	3 (NRSI)	Yes, PROSPERO	journal publication 10.1016/j.metabol.2021.154753 CRD42020203960
Burela, 2020	Peru	SR	people of all ages (general population)	chlorine dioxide, chlorine derivatives	clinical efficacy and safety in preventing or treating COVID-19, SARS, MERS	0	Yes, PROSPERO	journal publication 10.17843/rpmesp.2020.374.6330 CRD42020200641

Burton, 2020	Cochrane UK	SR	healthcare workers, not infected (high risk population)	antimicrobial mouthwashes and nasal sprays	incidence, safety	0	Yes, peer-reviewed Cochrane protocol	Cochrane review 10.1002/14651858.CD013626.PUB2
Flores-Genuino, 2020	Philippines	rapid SR	individuals at risk of exposure to COVID-19 (high risk population)	oral fatty acid supplementation	any clinical outcome	0	No	journal publication 10.47895/AMP.V5410.2443
Gbinigie, 2020	UK	rapid SR	people of all ages (general population)	zinc	clinical efficacy and safety (prophylaxis)	1 (NRSI)	No	preprint 10.12688/wellcomeopenres.16173.1

BCG=Bacillus Calmette-Guérin; COVID-19=Corona-Virus Disease 2019; CQ=Chloroquine; CS=Case Studies (case series, case report); DTA=Diagnostic Test Accuracy; HCQ=Hydroxychloroquine; ITS=Interrupted Time-Series; MA=Meta-Analysis; MERS=Middle East Respiratory Syndrome; NMA=Network Meta-Analysis; n.r.=not reported; NRSI=Non-Randomized Studies of Interventions (including, cohort studies, case-control-studies, cross-sectional studies); PPE=Personal Protective Equipment; RCT=Randomized Controlled Trial; SARS (CoV-2)=Severe Acute Respiratory Syndrome (Corona-Virus 2); SR=Systematic Review; UK=United Kingdom; vs.=versus
^acountry of institutional affiliation of corresponding and/or first author
^bExtraction is based solely on data presented in the abstract, as the full text is only available in Chinese